Nocturnal Enuresis Medication Market Report 2026

Nocturnal Enuresis Medication Market Overview

• Nocturnal Enuresis Medication market size has reached to $1.63 billion in 2025 • Expected to grow to $2.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.7% • Growth Driver: Rising Demand For Personalized Care Fueling The Growth Of The Market Due To Enhanced Treatment Effectiveness And Patient Adherence • Market Trend: Advancements In Treatment Options With Focus On Orally Disintegrating Tablets (ODT) For Enhanced Patient Convenience • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nocturnal Enuresis Medication Market?

Nocturnal enuresis medication refers to pharmaceutical treatments designed to manage and reduce involuntary urination during sleep, commonly known as bedwetting, particularly in children and sometimes in adults. The primary goal is to enhance bladder control, reduce the volume of urine produced overnight, or alter the body's natural sleep response to a full bladder. The main drug classes of nocturnal enuresis medication include desmopressin, imipramine, oxybutynin, combined pharmacotherapy, and antidepressants. Desmopressin is a synthetic hormone used to reduce nighttime urine production, commonly prescribed for treating conditions such as nocturnal enuresis (bedwetting). It is used for various age groups, including children, adolescents, adults, and the elderly, and is available in various formulations, such as tablets, liquid solutions, sprays, patches, and extended-release formulations. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Nocturnal Enuresis Medication Market Growth Forecast?

The nocturnal enuresis medication market size is expected to see strong growth in the next few years. It will grow to $2.26 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growth in pediatric urology care, rising demand for safer long-term therapies, advancements in drug formulations, increased diagnosis in adolescents and adults, expansion of online pharmacy access. Major trends in the forecast period include increasing use of desmopressin-based therapies, growing adoption of combination drug treatments, rising awareness of pediatric bedwetting management, expansion of extended-release formulations, increasing focus on long-term treatment safety.

Global Nocturnal Enuresis Medication Market Segmentation

1) By Drug Class: Desmopressin, Imipramine, Oxybutynin, Combined Pharmacotherapy 2) By Age Group: Children, Adolescents, Adults, Elderly 3) By Formulation Type: Tablets, Liquid Solutions, Sprays, Patches, Extended-Release Formulations 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Desmopressin: Oral Tablets, Nasal Sprays, Sublingual Tablets 2) By Imipramine: Oral Tablets, Extended-Release Capsules 3) By Oxybutynin: Immediate-Release Tablets, Extended-Release Tablets, Transdermal Patches, Syrups 4) By Combined Pharmacotherapy: Desmopressin And Oxybutynin, Desmopressin And Imipramine, Oxybutynin And Imipramine

What Are The Drivers Of The Nocturnal Enuresis Medication Market?

The increasing demand for personalized care is expected to fuel the growth of the nocturnal enuresis medication market going forward. Personalized care refers to a medical approach that tailors treatment and healthcare strategies to an individual's unique genetic profile, lifestyle, preferences, and specific health conditions, ensuring more targeted and effective outcomes. The growing demand for personalized care is due to advancements in medical technology that allow healthcare providers to tailor treatments based on each patient’s genetics, lifestyle, and health conditions, leading to more effective and targeted care. Personalized care supports nocturnal enuresis medication by tailoring treatment plans to an individual's specific medical history, lifestyle, and underlying causes, thereby improving the effectiveness and adherence to the therapy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA), a US-based federal agency, approved 16 new personalized treatments in 2023 for rare disease patients, up from 6 in 2022. Therefore, increasing demand for personalized care is driving the growth of the nocturnal enuresis medication industry. The increasing healthcare expenditure is expected to propel the growth of the nocturnal enuresis medication market going forward. Healthcare expenditure refers to the total spending on medical services, products, and public health by individuals, governments, and organizations within a specific period. The increasing healthcare expenditure is due to factors such as the increasing prevalence of chronic diseases, which require long-term management, ongoing treatment, and frequent medical interventions, leading to higher costs for medications, healthcare services, and specialized care. Increasing healthcare expenditure supports nocturnal enuresis medication by enabling greater investment in research, development, and access to advanced treatment options, thereby improving the availability and effectiveness of care for affected patients. For instance, in January 2024, according to Peterson-KFF Health System Tracker, a US-based non-profit data and analysis platform, US health spending was projected to reach $4.9 trillion in 2024, up 5% from $4.67 trillion in 2023. Therefore, increasing healthcare expenditure is driving the growth of the nocturnal enuresis medication industry.

Key Players In The Global Nocturnal Enuresis Medication Market

Major companies operating in the nocturnal enuresis medication market are Ferring Pharmaceuticals A/S, Serenity Pharmaceuticals LLC, Vantia Therapeutics Ltd., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Astellas Pharma Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Mylan N.V., Sandoz Group AG, Endo International plc, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC

Global Nocturnal Enuresis Medication Market Trends and Insights

Major companies operating in the nocturnal enuresis medication market are focusing on developing advanced solutions, such as orally disintegrating tablets (ODT), to offer ease of administration. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve or disintegrate quickly in the mouth without the need for water, making them ideal for patients with swallowing difficulties. For instance, in March 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched desmopressin orally disintegrating tablets (ODT) in Europe. Desmopressin ODT is specifically designed for the treatment of primary nocturnal enuresis, offering a convenient and easy-to-administer option that rapidly disintegrates in the mouth. This unique formulation is particularly beneficial for pediatric and elderly patients, as well as those with difficulty swallowing tablets. The launch highlights Adalvo’s dedication to providing high-quality, differentiated pharmaceutical products while improving patient access to vital therapies through strategic industry partnerships.

Regional Insights

North America was the largest region in the nocturnal enuresis medication market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nocturnal Enuresis Medication Market?

The nocturnal enuresis medication market consists of sales of fixed-dose combination drugs, nutraceuticals, and herbal supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nocturnal Enuresis Medication Market Report 2026?

The nocturnal enuresis medication market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nocturnal enuresis medication industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.